Skip to content

Praxis Precision Medicines

US · PRAX #1645 by market cap Listed 2020
300.43 -10.47 -3.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 7.28 Expensive vs history 83rd percentile
5-year average 4.44 · #437 of 514 in Biotechnology
P/E ratio -25.60 Cheap vs history 3rd percentile
5-year average -7.12 · forward -20.35
P/S ratio 1,228.96 Expensive vs history 94th percentile
5-year average 385.80 · forward 55.61 · #355 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Praxis Precision Medicines (PRAX) 8.40B -23.43 6.67 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value325.07 Economic moatNone UncertaintyVery High

Trading 8.2% below Morningstar's fair value estimate.

Fair value

Praxis Precision Medicines Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a price consistent with our quantitative fair value estimate, which has a very high uncertainty rating.

The firm's liquidity decreases our fair value estimate. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. Reflecting the firm's liquidity is its median trading volume over the past 60 days, which ranks in the top 40% globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. This contributes to our balanced fair value estimate.

The company's unfavorable dividend structure is an additional cause for concern. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, lies in the bottom 30% compared with peers globally. This could imply a planned dividend cut or relatively high share price, which further promotes our neutral price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is fairly-valued, this outperformance had a positive impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:15 · For reference only, not investment advice and not tailored to your situation.

Praxis Precision Medicines discussion 0 comments

Add a comment